**Core Concept**
The question revolves around the comparison of Raloxifene and Oestrogen therapy in post-menopausal women, focusing on their effects on bone density and cardiovascular health. **Selective Estrogen Receptor Modulators (SERMs)** like Raloxifene are known for their tissue-selective actions.

**Why the Correct Answer is Right**
Raloxifene has been shown to have **anti-estrogenic effects on the breast and uterus** while maintaining **estrogenic effects on bone**, making it a favorable option for preventing **osteoporosis** in post-menopausal women without increasing the risk of **breast cancer** or **endometrial cancer**.

**Why Each Wrong Option is Incorrect**
**Option A:** This choice is incorrect because Raloxifene does offer a reduced risk of breast cancer, which is an advantage over estrogen therapy.
**Option B:** Incorrect, as Raloxifene does provide benefits for bone health similar to estrogen.
**Option C:** This is also incorrect because Raloxifene is known to have a more favorable side effect profile concerning the uterus compared to estrogen therapy.

**Clinical Pearl / High-Yield Fact**
A key point to remember is that Raloxifene, being a SERM, can have different effects on various tissues, making it useful for specific conditions like osteoporosis in post-menopausal women without the increased risk of certain cancers associated with estrogen therapy.

**Correct Answer:** D. Increased risk of venous thromboembolism is a side effect shared by both Raloxifene and Oestrogen, not an advantage of Raloxifene over Oestrogen.